Sustainable Growth Advisers LP trimmed its holdings in STERIS plc (NYSE:STE - Free Report) by 3.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,383,218 shares of the medical equipment provider's stock after selling 55,981 shares during the quarter. STERIS comprises about 1.4% of Sustainable Growth Advisers LP's portfolio, making the stock its 29th biggest position. Sustainable Growth Advisers LP owned approximately 1.40% of STERIS worth $284,334,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in STE. Ashton Thomas Securities LLC acquired a new position in STERIS in the third quarter valued at approximately $25,000. Human Investing LLC bought a new stake in shares of STERIS in the 4th quarter valued at $31,000. Anfield Capital Management LLC lifted its position in shares of STERIS by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 91 shares during the period. Central Pacific Bank Trust Division boosted its stake in STERIS by 65.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 76 shares in the last quarter. Finally, Manchester Capital Management LLC grew its holdings in STERIS by 182.7% in the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock worth $44,000 after purchasing an additional 137 shares during the period. Institutional investors own 94.69% of the company's stock.
STERIS Stock Up 0.2 %
Shares of NYSE STE traded up $0.48 during trading on Tuesday, hitting $228.29. The stock had a trading volume of 454,011 shares, compared to its average volume of 500,399. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.13 and a quick ratio of 1.40. The firm has a fifty day moving average of $219.65 and a two-hundred day moving average of $222.31. STERIS plc has a 12 month low of $197.82 and a 12 month high of $248.24. The company has a market capitalization of $22.43 billion, a PE ratio of 48.47 and a beta of 0.92.
STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. As a group, equities research analysts forecast that STERIS plc will post 9.08 EPS for the current fiscal year.
STERIS Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.00%. The ex-dividend date is Thursday, February 20th. STERIS's dividend payout ratio is presently 48.41%.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on STE. Piper Sandler increased their price objective on shares of STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. JMP Securities reissued a "market outperform" rating and issued a $265.00 price objective on shares of STERIS in a research note on Thursday, February 6th. Finally, Stephens reaffirmed an "overweight" rating and set a $240.00 target price on shares of STERIS in a research report on Thursday, February 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, STERIS currently has an average rating of "Moderate Buy" and an average target price of $258.75.
Read Our Latest Stock Report on STE
About STERIS
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Featured Stories
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
